Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio-Reference-Cited by-同舟云学术

Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio

Published:2018-09-26 Issue:2 Volume:33 Page:527-531
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Muchtar Eli^ORCID,Dispenzieri Angela,Leung Nelson^ORCID,Lacy Martha Q.,Buadi Francis K.,Dingli David,Hayman Suzanne R.,Kapoor Prashant,Hwa Yi Lisa,Fonder Amie,Hobbs Miriam,Gonsalves Wilson,Kourelis Taxiarchis V.,Warsame Rahma,Russell Stephen J.,Lust John A.,Lin Yi,Go Ronald S.^ORCID,Zeldenrust Steven R.,Kyle Robert A.,Rajkumar S. Vincent,Kumar Shaji K.^ORCID,Gertz Morie A.

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/s41375-018-0258-y.pdf

Reference9 articles.

1. Dispenzieri A, Lacy MQ, Katzmann JA, Rajkumar SV, Abraham RS, Hayman SR, et al. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood. 2006;107:3378–83.

2. Kumar S, Dispenzieri A, Katzmann JA, Larson DR, Colby CL, Lacy MQ, et al. Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features. Blood. 2010;116:5126–9.

3. Lachmann HJ, Gallimore R, Gillmore JD, Carr-Smith HD, Bradwell AR, Pepys MB, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol. 2003;122:78–84.

4. Sanchorawala V, Seldin DC, Magnani B, Skinner M, Wright DG. Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis. Bone Marrow Transplant. 2005;36:597–600.

5. Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30:4541–9.

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Autologous stem cell transplantation in AL amyloidosis: Muddy waters;Blood Reviews;2024-08

2. AL amyloidosis: an overview on diagnosis, staging system, and treatment;Frontiers in Hematology;2024-05-08

3. AL amyloidosis: Singapore Myeloma Study Group consensus guidelines on diagnosis, treatment and management;Annals of the Academy of Medicine, Singapore;2023-11-29

4. Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA;Annals of Hematology;2023-03-02

5. Immunoglobulin Light Chain Amyloidosis: Diagnosis and Risk Assessment;Journal of the National Comprehensive Cancer Network;2023-01